A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol. by Bhat, Y et al.
STUDY PROTOCOL Open Access
A mixed methodology, non-interventional
study to evaluate the use of direct oral
anticoagulants in UK clinical practice for
patients with a first stroke associated with
non-valvular atrial fibrillation: study
protocol
Yaqoob Bhat1, Anand Dixit2, Amit Mistri3, Bhavini Patel4, Sadat Haider Quoraishi5 and James Uprichard4*
Abstract
Background: Treatment with anticoagulants, including direct oral anticoagulants (DOACs), should be considered
for patients diagnosed with atrial fibrillation (AF) deemed at risk of ischaemic stroke. There are limited real world
data related to the characteristics of patients with non-valvular AF who were not taking anticoagulants at the time
of first ischaemic stroke and their subsequent DOAC treatment for the secondary prevention of stroke. Furthermore,
little is known about patient adherence and experiences of DOAC treatment, especially for patients with non-
valvular AF receiving DOAC therapy for the secondary prevention of stroke.
Methods: This is a UK mixed methodology, non-interventional study, involving retrospective and prospective
medical record reviews and a prospective patient survey, in progress in six UK National Health Service secondary/
tertiary care centres. The study comprises two groups of patients. Group 1 will include 300 eligible consenting
patients with a first ischaemic stroke associated with non-valvular AF untreated with anticoagulants in the 12
months prior to stroke. Group 2 will include a subgroup of 150 patients from Group 1 initiated on one of the
DOACs targeting activated Factor X (n = 50 on apixaban, n = 50 on edoxaban and n = 50 on rivaroxaban). The
primary endpoint of the study is the CHA2DS2-VASc Risk Score prior to initiation of anticoagulation for patients
included in Group 1. Secondary endpoints to be evaluated in Group 1 include patient demographics, clinical
characteristics, relevant medical history, anticoagulant therapy initiated for secondary prevention of stroke, and
relevant concomitant medication. Secondary endpoints to be evaluated in Group 2 include the time between
stroke and DOAC initiation; prescribing of DOACs, other anticoagulants and concomitant medication; clinical
assessments and hospital resource use; patient reported outcome measures, including the Morisky Medication
Adherence Scale questionnaire and the Treatment Satisfaction Questionnaire for Medication.
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Discussion: This mixed methodology study will provide new real world insights into the characteristics and
management pathways and patient-reported experiences of this important group of patients. It is anticipated that
the results of this study will provide the medical community and patients with important information to inform
clinical decision-making and help facilitate meaningful improvements in the care of patients with non-valvular AF.
Keywords: Non-valvular atrial fibrillation, Ischaemic stroke, CHA2DS2-VASc risk score, Anticoagulant, Direct oral
anticoagulants, Treatment adherence, Treatment satisfaction, Hospital resource use
Background
Atrial fibrillation (AF) is the most common chronic car-
diac arrhythmia, which often remains undiagnosed and is
associated with a significantly increased risk for thrombo-
embolic stroke [1–3]. It has been estimated by the Stroke
Association that approximately 20% of the more than 100,
000 strokes occurring annually in the United Kingdom
(UK) are associated with AF [4]. The UK National Insti-
tute for Health and Care Excellence recommends that
anticoagulation is considered for patients diagnosed with
AF who are deemed to be at risk of stroke, as assessed by
the CHA2DS2-VASc score [5, 6].
Direct oral anticoagulants (DOACs) are a class of oral
anticoagulants that have been developed and introduced
to healthcare systems across the world over the past dec-
ade. The first DOAC to market, dabigatran, is a direct
thrombin inhibitor which, like warfarin, has been the
subject of numerous real world observational research
studies [7, 8]. The three DOACs most widely used cur-
rently in the UK for the primary and secondary preven-
tion of stroke in patients with non-valvular AF (the most
common form of AF) are direct inhibitors of activated
factor X (anti-FXa DOACs, namely apixaban, edoxaban
and rivaroxaban) [5, 9–11]. Although some real world
studies have evaluated the use and effectiveness of apixa-
ban and rivaroxaban in patients with AF [12–14], there
are limited data related to the characteristics of patients
who were not taking anticoagulants at the time of first
ischaemic stroke. There are also limited data related to
use of anti-FXa DOACs in routine clinical practice since
the introduction of edoxaban in 2015, the last DOAC to
market in the UK. Furthermore, while guidance on pre-
scribing each of the anti-FXa DOACs is available [9–11],
this may not reflect how they are prescribed and taken
by patients treated in routine clinical practice. Patient-
related factors, including adherence, how patients per-
ceive the benefits of treatment (including their experi-
ence and satisfaction with the treatment and overall
care) may impact on treatment effectiveness. However,
little is known about the extent to which patients adhere
to anti-FXa DOAC treatment and their perceptions of
anti-FXa DOAC treatment, especially for patients with
AF receiving DOAC therapy for the secondary preven-
tion of stroke.
Methods/design
Aim and objectives
The aim of this mixed-methodology study is to evaluate
the real world use of anticoagulation, in particular anti-
FXa DOAC treatment (apixaban, edoxaban and rivarox-
aban) in routine UK clinical practice in terms of patient
characteristics, management pathways and patient-
reported experiences of anticoagulation initiated follow-
ing a first ischaemic stroke associated with non-valvular
AF for patients who were not receiving anticoagulant
therapy in the 12months prior to the stroke.
The primary objective of this study is to describe the
demographics, clinical characteristics and medical his-
tory of patients with AF presenting with a first ischaemic
stroke who were not treated with anticoagulants in the
12months prior to the stroke, according to the type of
anticoagulant treatment subsequently prescribed for sec-
ondary stroke prevention (apixaban, edoxaban, rivaroxa-
ban, warfarin, dabigatran, other anticoagulants or a
documented decision not to initiate anticoagulation).
Secondary study objectives will be evaluated only in pa-
tients treated with anti-FXa DOACs (apixaban, edoxa-
ban, rivaroxaban), including describing the management
pathways of patients initiated on anti-FXa DOAC treat-
ment for secondary prevention of stroke; describing hos-
pital resource use and the clinical assessments associated
with anti-FXa DOAC treatment; describing patient-
reported adherence to anti-FXa DOAC treatment; and
describing patient-reported experience and satisfaction
with anti-FXa DOAC treatment.
Study design and setting
This is a UK mixed methodology, non-interventional
study, involving retrospective and prospective medical
record reviews and a prospective patient survey, which is
in progress in six UK National Health Service (NHS)
secondary and tertiary care centres. Study centres have
been selected to provide good geographic representation
of centres experienced in prescribing apixaban, edoxa-
ban and rivaroxaban for the secondary prevention of is-
chaemic stroke in patients with non-valvular AF. The
key elements of study design are summarised in Fig. 1.
The index event is the diagnosis of first ischaemic stroke
associated with AF. The pre-index observation period is
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the 12-month period prior to the index event. The post-
index observation period is the one month period fol-
lowing the index event. The post-DOAC observation
period is the period from initiation of anti-FXa DOAC
treatment up to a maximum of 7 months (6 months + 1
month window for completion of questionnaires) post-
initiation.
Patients
Two groups of patients will be included in the study.
Group 1 will comprise 300 patients with a first ischae-
mic stroke that was associated with non-valvular AF
who were not treated with anticoagulants in the 12
months prior to the stroke. The primary study objective
will be evaluated in Group 1. Group 2 will be a subgroup
of 150 patients from Group 1, comprising 50 patients
initiated on apixaban, 50 patients initiated on edoxaban
and 50 patients initiated on rivaroxaban. The secondary
study objectives will be evaluated in Group 2.
Patients will be eligible for inclusion in Group 1 if they
are aged ≥18 years at time of presentation to the study
centre with a first ischaemic stroke which, in the clini-
cian’s opinion, is associated with non-valvular AF.
Eligible patients must not have been prescribed antico-
agulants for any indication in the 12months prior to
stroke diagnosis, or have a history of haemorrhagic
stroke or transient ischemic attack or have a severe cog-
nitive or emotive deficit at the time of consent. Patients
Fig. 1 Study design and observation periods. Group 1: retrospective data collection for 300 eligible and consenting patients who present with
first stroke associated with non-valvular atrial fibrillation (index event). The pre-index observation period is the 12-month period prior to the index
event. The post-index observation period is the one month period following the index event Group 2: Prospective data collection for the first
150 eligible and consenting patients from Group 1 who commence treatment with apixaban (n = 50), edoxaban (n = 50), or rivaroxaban (n = 50).
The post-DOAC observation period is from initiation of anti-FXa DOAC treatment up to a maximum of 7 months (6 months + 1month window
for completion of questionnaires) post-initiation. The baseline questionnaire will be completed within one month following anti-FXa DOAC
initiation. The three-month questionnaire will be completed within the period beginning one week prior to and ending one month after the
three-month post-initiation time point. The six-month questionnaire will be completed within the period beginning one week prior to and
ending one month after the six-month post-initiation time point
Bhat et al. BMC Neurology          (2019) 19:306 Page 3 of 8
will be ineligible for inclusion in Group 1 if their medical
records are not available for review or if they are unwill-
ing or unable to give written informed consent for
researcher access to their medical records. Patients in
Group 1 will be eligible for inclusion in Group 2 if they
are initiated on apixaban, edoxaban or rivaroxaban for
secondary prevention of stroke. Patients in Group 1 will
be ineligible for inclusion in Group 2 if they are un-
willing or unable to complete the patient-reported
questionnaires.
Patients will be identified and recruited prospectively
during a one-year period from the point of approval to
commence recruitment at participating centres. Poten-
tially eligible patients will be identified by members of
the direct care team from local department databases.
Patients fulfilling the Group 1 eligibility criteria will be
approached to provide written informed consent for
retrospective data collection from their medical records
by members of the direct care team. Patients will be
approached in consecutive chronological order, accord-
ing to the date of stroke diagnosis, until the required
sample size or the centre-specific recruitment target is
reached. The first 50 eligible and consenting patients
initiated on either apixaban, edoxaban or rivaroxaban
at any of the study centres during the one year recruit-
ment period will also be included in Group 2. Although
centres included in the study will have experience of
prescribing all three DOACs of interest, it is likely that
some centres will favour a particular anti-FXa DOAC
(although feasibility exercises suggest that the favoured
DOAC will vary between centres). Recruitment of
patients into Group 2 will be evaluated on an ongoing
basis to monitor whether a study centre is predomin-
ately favouring one type of DOAC. To ensure there is
balanced enrolment of patients into the Group 2 apixa-
ban, edoxaban and rivaroxaban sub-groups, centre
enrolment targets may be implemented to ensure bal-
anced representation across centres in order to minim-
ise bias.
Data sources and data collection
Retrospective medical record review
Data will be collected retrospectively from the hospital
medical records of patients included in Group 1 in order
to describe patient demographics and clinical character-
istics and relevant medical history, including the compo-
nents required to assess the CHA2DS2-VASc risk score
(age, sex, history of congestive heart failure, hyper-
tension, diabetes mellitus, stroke/transient ischaemic
attack/thromboembolism, vascular disease). Where rele-
vant, primary care data will also be requested from pa-
tients’ General Practitioners (GP). Data on the type of
anticoagulant treatment prescribed for secondary pre-
vention of stroke will be collected retrospectively for the
one month post-index observation period. These time
periods were chosen to ensure sufficient time to capture
relevant data related to patient demographic and clinical
characteristics prior to first stroke, accounting for varia-
tions in appointment timing and scheduling seen in rou-
tine clinical practice. A prior scoping exercise involving
five healthcare professionals suggested that the data re-
quired to evaluate the primary endpoint (summary of
CHA2DS2-VASc risk characteristics) are likely to be rou-
tinely recorded. Furthermore, the CHA2DS2-VASc risk
score has been shown to be a useful predictor of patient
outcomes over a 12 month period [15] and so a 12
month pre-index observation period was deemed appro-
priate. All data obtained from medical records will be re-
corded in electronic case report forms (eCRFs) designed
specifically for the study, using a secure web-based elec-
tronic data capture system.
Prospective medical record review
Details of anti-FXa DOAC treatment and hospital re-
source utilisation will be sourced prospectively from the
hospital medical records of patients included in Group 2
for the six-month period following initiation of anti-FXa
DOAC treatment and entered into the eCRFs. In certain
cases, it may be necessary to contact the patient’s GP to
obtain information from primary care records. However,
it is anticipated from feasibility assessments that import-
ant information about the patient’s treatment will be
captured within the secondary care records, as it is likely
that patients will be referred back into secondary care
should any adjustment to their anticoagulant treatment
be needed.
Prospective patient survey
Patient-reported outcome data will be collected pro-
spectively from patients in Group 2 via questionnaires
administered at baseline (initiation of anti-FXa DOAC
treatment + 1month), and at 3 months (− 1 week/+ 1
month) and 6months (− 1 week/+ 1month) after initi-
ation of anti-FXa DOAC treatment for secondary pre-
vention of stroke. These time-points were chosen in
order to allow an adequate amount of time between as-
sessment points for DOAC treatment to take effect.
Questionnaires will be administered face-to-face if pa-
tients are attending clinic at the relevant time point; they
will be reminded of the study requirements and will be
given the opportunity to decide whether or not they
would still like to take part, prior to the questionnaire
being administered. Otherwise questionnaires will be
administered via telephone, which is a methodology for
administration of patient questionnaires that has been
used in prior studies, including a study relating to edox-
aban treatment [16]. Where questionnaires are adminis-
tered by telephone, the questionnaires will be posted to
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patients by members of their direct care team at the
relevant time points to give patients an opportunity to
contemplate their responses and complete the question-
naires in advance. Patients will be contacted by tele-
phone to advise them that the questionnaire has been
posted, to remind them of the study requirements and
to ensure that they are still willing to participate in the
study. A member of the direct care team or an external
researcher will contact patients at an agreed date and
time to collect their responses via telephone. The ques-
tions will be read to patients as written on the paper ver-
sion and patients’ responses will be entered directly into
the eCRF.
Study endpoints and variables
The primary endpoint of the study is the CHA2DS2-
VASc Risk Score (scores range from 0 to 9) prior to
initiation of anticoagulation for patients included in
Group 1. Secondary endpoints to be evaluated in pa-
tients in Group 1 include patient demographics (in-
cluding age, sex, body mass index [BMI], smoking
status, alcohol use, ethnicity) and clinical characteris-
tics (including time from AF diagnosis until stroke,
recorded stroke severity, location of presentation with
stroke [e.g. Emergency Department (ED), inpatient,
outpatient, GP], and key clinical and laboratory evalu-
ations at the time of stroke (including renal function,
liver function and blood parameters), relevant medical
history (including history of congestive heart failure,
hypertension, diabetes mellitus, vascular disease [in-
cluding myocardial infarction, aortic plaque, periph-
eral vascular disease], renal disease, hepatic disease),
anticoagulant therapy initiated for secondary pre-
vention of stroke, and relevant concomitant medica-
tion at the time of stroke and prescribed in the one
month period after stroke. Secondary endpoints to be
evaluated in patients in Group 2 include: the time be-
tween index event and date of anti-FXa DOAC initi-
ation; anti-FXa DOACs and other anticoagulants
prescribed during the post-DOAC observation period
(including dose, and dosing frequency and reason for
choice of first DOAC treatment, changes in dose and
reasons for dose changes, DOAC discontinuation,
time from initiation to discontinuation of first DOAC
and reason(s) for discontinuation, anticoagulant treat-
ments subsequently prescribed and reason(s) for
choice/discontinuation); relevant medications newly
prescribed in the post-DOAC observation period;
clinical assessments (types and results of clinical as-
sessments); hospital resource use (number, type [out-
patient, inpatient, ED, other; planned or unplanned],
setting [face-to-face, telephone, other], reason for hos-
pital visits/consultations, length of stay for inpatient
admissions, time to first follow-up visit from date of
DOAC initiation) during the post-DOAC observation
period.
Patient reported outcome measures include the
Morisky Medication Adherence Scale (MMAS-8) ques-
tionnaire [17] and the Treatment Satisfaction Question-
naire for Medication (TSQM) questionnaire [18]. The
MMAS-8 is a short, eight-item measure of treatment
adherence that has previously been used to assess ad-
herence to DOAC treatment in patients with venous
thromboembolism [19]. The MMAS has been used
widely in different diseases, populations and countries
and has been administered face-to-face or via telephone
[20–22]. The MMAS-8 is quicker to complete and has
a higher degree of concordance with more objective
measures of treatment (such as pharmacy fill data or
electronic monitoring devices) than many other self-
report measures [20]. In order to gain additional insight
into recent levels of treatment adherence, patients will
also be asked to report whether, how and how often
they had taken their current anti-FXa DOAC treatment
in the past seven days using a bespoke questionnaire.
The TSQM is a widely validated general measure of
treatment satisfaction which has been used for a variety
of treatments and disease areas, including for measur-
ing levels of patient satisfaction with anticoagulation
treatment [23], and has been administered face-to face
or via telephone [22]. The bespoke questionnaire will
be administered to gain an understanding of the general
experiences of patients with regard to other aspects of
their care, such as communication, education about
anti-FXa DOAC treatment and overall hospital
experience.
Ethical considerations
Patients will be identified in all study documents and
questionnaires by a unique study identification num-
ber that will be used to link multiple study records
for each participant. No personally identifiable infor-
mation on any participant will be collected or re-
moved from the participating centres in order to
preserve patient confidentiality. Patients will provide
written informed consent according to the Research
Ethics Committee (REC)-approved protocol and con-
sent materials. Only patients providing written in-
formed consent will be included in the study and no
data collection on an individual will take place until
their written informed consent has been obtained.
Participants will have the right to withdraw their con-
sent at any time, without giving a reason and without
prejudice to their normal care. NHS management ap-
proval for local conduct of the study and the sharing
of pseudonymised patient data will be sought via the
Research and Development department in each par-
ticipating centre.
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Statistical methods
Study sample size
Study endpoints will be described for the overall patient
population and in patients stratified by anticoagulant
treatment received; however, no formal comparisons
between groups will be made. Therefore the required
sample size was estimated based on precision (95% con-
fidence limits) rather than statistical power. For Group
1 a sample size of 300 patients is considered sufficient
to reliably describe the demographics and clinical char-
acteristics of the study population. Based on feasibility
interviews with a small sample of UK clinicians it is an-
ticipated that approximately 80% of patients in Group 1
are likely to be prescribed a DOAC for secondary pre-
vention of stroke. Therefore, a sample size of 150 pa-
tients in Group 2 distributed evenly between patients
initiated on apixaban, edoxaban and rivaroxaban is con-
sidered feasible. A sample size of 50 patients treated
with each of the anti-FXa DOACs is considered suffi-
cient to give reliable estimates of patient adherence
based on scores from a previously published study of
DOAC adherence [24]. For a sample of 50 patients with
a mean adherence score of 7.2 and a standard deviation
of 1.2, the lower and upper confidence limits are ex-
pected to be between 6.9 and 7.5, indicating the sample
size is sufficient to provide a reliable estimate of mean
adherence score.
Data analysis
Statistical analyses, including any data preparation prior to
analysis, will be carried out using Stata v14 (StataCorp
LLC) and Microsoft Excel (2010). Data from all centres
will be pooled for analysis. Study endpoints will be
presented as descriptive statistics of central tendency
(median; arithmetic mean or geometric mean) and disper-
sion (interquartile range [IQR] and/or range; standard de-
viation [SD] and/or 95% confidence intervals [95% CI])
and/or frequencies and percentages, as appropriate for the
type and distribution of the variables.
Total scores for the validated patient-reported ques-
tionnaires will be derived in accordance with published
scoring algorithms for each measure [17, 18, 25]. Ana-
lyses will be conducted using only the results of those
patients with data available.
Subgroup and sensitivity analyses
All endpoints evaluated in Group 2 will be stratified
according to the anti-FXa DOAC first prescribed
(apixaban, edoxaban, rivaroxaban). Patient-reported
outcomes will also be analysed separately for patients
remaining on first anti-FXa DOAC treatment and
those switching DOAC treatment during the post-
DOAC observation period, in order to explore the
relationship between patient-related factors and
decisions to switch treatments. No sensitivity analyses
are planned.
Limitations of the research methods
Based on feasibility assessments it is expected that all
relevant data to evaluate the CHA2DS2-VASc risk
score will be available for all patients. However, it is
possible that some or all of the required components
needed to calculate the CHA2DS2-VASc score will be
unavailable for some patients, which may introduce
bias in terms of a reduction in the sample size and
may lead to underestimation of stroke risk. The
exclusion of patients with persisting cognitive or emo-
tive deficit at the time of consent may lead to an
underestimation of hospital resource use; patient-
reported outcomes may also not be representative of
the wider patient population. In addition, primary
care data following discharge home from hospital
after stroke and/or data relating to patient manage-
ment prior to stroke may also not be available for all
patients, which may affect the related endpoints. This
is a descriptive study and no comparative analyses or
analyses to control for confounding factors will be
carried out. As such, no inferences about causal rela-
tionships between different DOACs and study end-
points and how treatments compare to each other
will be made. For patient-reported measures, the data
will rely on the completeness of the answers provided
by participants, which will not be queried or other-
wise followed up to clarify inconsistencies or omis-
sions. The importance of providing honest and
complete responses at each time point will be empha-
sised to patients; data may however be subject to
patient recall and reporting bias. Patient-reported data
based on recall (for example, for adherence to medi-
cation) may also be subject to recall bias and/or
reporting bias.
Discussion
Despite the increased risk of stroke in patients with
AF, recent data from the Sentinel Stroke National
Audit Programme indicate that more than 40% of
patients with known AF were not taking anticoagu-
lants at the time of presentation with stroke in the
period from April 2017 to March 2018 [26]. This
mixed methodology study will provide new real world
insights into the characteristics, management path-
ways and patient-reported experiences of patients who
were not receiving anticoagulant therapy in the 12
months prior to first ischaemic stroke associated with
non-valvular AF. The mixed methodology approach,
involving a combination of retrospective and pro-
spective data collection, will enable collection of data
from medical records before and after first stroke in a
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timely fashion and also enable patient-reported data
to be collected at relevant time-points during DOAC
treatment. It is anticipated that the results of this
study will provide the medical community and
patients with important information to inform clinical
decision-making and help facilitate meaningful
improvements in the care of patients with non-
valvular AF.
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